CLDX (Celldex Therapeutics) Cyclically Adjusted Book per Share: $15.02 (As of Mar. 2026)


CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $35.23
GF Value $6.88
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Cyclically Adjusted Book per Share?

Celldex Therapeutics CLDX +3.43% 57 Cyclically Adjusted Book per Share is $15.02 as of Mar. 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $6.88 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Celldex Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $6.853. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $15.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Celldex Therapeutics's average Cyclically Adjusted Book Growth Rate was -24.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -17.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -11.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Celldex Therapeutics was 6.30% per year. The lowest was -18.30% per year. And the median was -8.80% per year.

As of today (2026-06-27), Celldex Therapeutics's current stock price is $35.23. Celldex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $15.02. Celldex Therapeutics's Cyclically Adjusted PB Ratio of today is 2.35.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Celldex Therapeutics was 2.64. The lowest was 0.05. And the median was 1.14.


Celldex Therapeutics  (NAS:CLDX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Celldex Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=35.23/15.02
=2.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Celldex Therapeutics was 2.64. The lowest was 0.05. And the median was 1.14.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Celldex Therapeutics Cyclically Adjusted Book per Share Related Terms


Celldex Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Cyclically Adjusted Book per Share Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.89 28.42 25.02 21.32 15.91

Celldex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.93 18.57 17.27 15.91 15.02

CLDX vs IMNM, ELVN, VERA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PB Ratio falls into.


CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celldex Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.853/330.2130*330.2130
=6.853

Current CPI (Mar. 2026) = 330.2130.

Celldex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 35.422 241.018 48.531
201609 32.162 241.428 43.990
201612 33.038 241.432 45.187
201703 29.939 243.801 40.550
201706 27.249 244.955 36.733
201709 24.884 246.819 33.292
201712 25.595 246.524 34.284
201803 14.028 249.554 18.562
201806 12.262 251.989 16.068
201809 11.402 252.439 14.915
201812 10.375 251.233 13.637
201903 8.773 254.202 11.396
201906 7.399 256.143 9.539
201909 6.374 256.759 8.197
201912 5.540 256.974 7.119
202003 4.721 258.115 6.040
202006 6.099 257.797 7.812
202009 5.813 260.280 7.375
202012 5.286 260.474 6.701
202103 4.901 264.877 6.110
202106 4.601 271.696 5.592
202109 9.359 274.310 11.266
202112 8.977 278.802 10.632
202203 8.515 287.504 9.780
202206 7.807 296.311 8.700
202209 7.334 296.808 8.159
202212 6.911 296.797 7.689
202303 6.408 301.836 7.010
202306 5.873 305.109 6.356
202309 5.220 307.789 5.600
202312 7.680 306.746 8.268
202403 12.723 312.332 13.451
202406 12.276 314.175 12.903
202409 11.846 315.301 12.406
202412 11.254 315.605 11.775
202503 10.590 319.799 10.935
202506 9.871 322.561 10.105
202509 9.005 324.800 9.155
202512 7.921 324.054 8.072
202603 6.853 330.213 6.853

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $15.02 mean?
Celldex Therapeutics (CLDX) has a Cyclically Adjusted Book per Share of $15.02 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Cyclically Adjusted Book per Share too high?
Celldex Therapeutics' current Cyclically Adjusted Book per Share is $15.02. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Cyclically Adjusted Book per Share compare to IMNM and ELVN?
Celldex Therapeutics' Cyclically Adjusted Book per Share of $15.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Cyclically Adjusted Book per Share is $15.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is $15.02. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Cyclically Adjusted Book per Share is $15.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Cyclically Adjusted Book per Share: $15.02
  • GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.23
Price
$6.88
GF Value